Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry
Kasiske, Bertram L. , Ahn, Yoon Son, Conboy, Michael, Dew, Mary Amanda , Folken, Christian, Levan, Macey L. , Lentine, Krista L. , Matas, Arthur J. , Newell, Kenneth A. , Massie, Allan B. , Musgrove, Donald, Taler, Sandra J. , Wang, Jeffrey , Israni, Ajay K. , Rudow, Dianne LaPointe , Snyder, Jon J. , Waterman, Amy D

Mayo Clinic

Transplantation Direct | April 23, 2021 | Volume: 7 | Issue: 5 | Pages: e689

10.1097/txd.0000000000001143 | PMID 33912656 Get It

Background. Gaps in our knowledge of long-term outcomes affect decision making for potential living kidney donors. Methods. The Scientific Registry of Transplant Recipients was asked to determine the feasibility of a candidate registry. Results. Ten living kidney donor programs evaluated 2107 consecutive kidney donor candidates; 2099 of 2107 (99.6%) completed evaluations, 1578 of 2099 (75.2%) had a decision, and 790 of 1578 (50.1%) were approved to donate as of March 12, 2020. By logistic regression, candidates most likely to be approved were married or had attended college or technical school; those least likely to be approved had ≥1 of the following characteristics: Black race, history of cigarette smoking, and higher blood pressure, higher triglycerides, or higher urine albumin-to-creatinine ratios. Reasons for 617 candidates not being approved included medical issues other than chronic kidney disease risk (25.3%), chronic kidney disease risk (18.5%), candidate withdrawal (15.2%), recipient reason (13.6%), anatomical risk to the recipient (10.3%), noneconomic psychosocial (10.3%), economic (0.5%), and other reasons (6.4%). Conclusions. These results suggest that a comprehensive living donor registry is both feasible and necessary to assess long-term outcomes that may inform decision making for future living donor candidates. There may be socioeconomic barriers to donation that require more granular identification so that active measures can address inequities. Some candidates who did not donate may be suitable controls for discerning the appropriateness of acceptance decisions and the long-term outcomes attributable to donation. We anticipate that these issues will be better identified with modifications to the data collection and expansion of the registry to all centers over the next several years.
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
Panés, Julián , Vermeire, Séverine , Dubinsky, Marla C. , Loftus, Edward V. , Lawendy, Nervin, Wang, Wenjin , Salese, Leonardo , Su, Chinyu , Modesto, Irene , Colombel, J F. , Loftus, Edward V , Panes, Julian , Vermeire, Séverine , Guo, Xiang , Colombel, Jean‐Frédéric

Mayo Clinic

Journal of Crohn's and Colitis | April 22, 2021 | Volume: 15 | Issue: 11 | Pages: 1852-1863

10.1093/ecco-jcc/jjab065 | PMID 33884415 Get It

Abstract Background and Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-treatment following treatment interruption in patients with ulcerative colitis. Methods Here, patients with clinical response to tofacitinib 10 mg b.d. induction therapy were randomised to receive placebo in OCTAVE Sustain. Those experiencing treatment failure after Week 8 of OCTAVE Sustain entered OCTAVE Open and re-initiated tofacitinib 10 mg b.d. [re-treatment subpopulation]; efficacy and safety data are presented up to Month 36 of OCTAVE Open. Results Median time to treatment failure following interruption was 169 (95% confidence interval [CI], 94.0–179.0) and 123 [95% CI, 91.0–168.0] days for induction remitters, and induction responders but non-remitters, respectively. Following re-treatment with tofacitinib, rates (non-responder imputation after a patient discontinued; latest observation carried forward imputation after a patient advanced to a subsequent study [NRI-LOCF]) of clinical response, remission, and endoscopic improvement were 74.0%, 39.0%, and 55.0% at Month 2, and 48.5%, 37.4%, and 42.4% at Month 36, respectively. Among induction remitters and induction responders but non-remitters, clinical response rates at Month 36 were 60.6% and 42.4% [NRI-LOCF], respectively. Efficacy was recaptured regardless of prior tumour necrosis factor inhibitor failure status. The safety profile of tofacitinib 10 mg b.d. re-treatment was consistent with the overall cohort and demonstrated no new safety risks associated with exposure of ≤36 months. Conclusions Median time to treatment failure was numerically higher in induction remitters versus induction responders but non-remitters. Following treatment interruption, efficacy was safely and successfully recaptured with tofacitinib 10 mg b.d. re-treatment in a substantial proportion of patients [ClinicalTrials.gov:NCT01458574;NCT01470612].
Procyanidin C1 is a natural agent with senolytic activity against aging and age-related diseases
Xu, Qixia, Li, Zi , Liu, Hanxin , Wang, Ying , He, Ruikun , Zhang, Xuguang , Campisi, Judith , Kirkland, James L. , Fu, Qiang , Li, Zi, Lin, Xu , Sun, Yu

Mayo Clinic

No container title available | April 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-421222/v1 Get It

Abstract Aging causes functional decline of multiple organs and increases the risk of age-related pathologies. In advanced lives, accumulation of senescent cells, which develop the senescence-associated secretory phenotype (SASP), promotes chronic inflammation and causes diverse conditions. Here we report the frontline outcome of screening a natural product library with human primary stromal cells as an experimental model. Multiple candidate compounds were assayed, and grape seed extract (GSE) was selected for further investigation due to its leading capacity in targeting senescent cells. We found procyanidin C1 (PCC1), a polyphenolic component, plays a critical role in mediating the antiaging effects of GSE. PCC1 blocks the SASP expression when used at low concentrations. Importantly, it selectively kills senescent cells upon application at higher concentrations, mainly by enhancing production of reactive oxygen species (ROS) and disturbing mitochondrial membrane potential, processes accompanied by upregulation of Bcl-2 family pro-apoptotic factors Puma and Noxa in senescent cells. PCC1 depletes senescent cells in treatment-damaged tumor microenvironment (TME) and enhances therapeutic efficacy when combined with chemotherapy in preclinical assays. Intermittent administration of PCC1 to both senescent cell-implanted mice and naturally aged animals alleviated physical dysfunction and prolonged post-treatment survival, thus providing substantial benefits in late life stage. Together, our study identifies PCC1 as a distinct natural senolytic agent, which may be exploited to delay aging and control age-related pathologies in future medicine.
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
Parikh, Sameer A. , Rabe, Kari G. , Kay, Neil E. , Call, Timothy G. , Ding, Wei , Leis, José F., Muchtar, Eli , Wang, Yucai , Koehler, Amber B. , Schwager, Susan M., Lesnick, Connie , Kleinstern, Geffen , Dyke, Daniel Van, Hanson, Curtis A. , Braggio, Esteban , Shanafelt, Tait D. , Muchtar, E , Wang, Yucai , Koehler, Amber B , Van Dyke, Daniel, Braggio, Esteban , Chaffee, Kari G. , Kay, Neil E , Ding, Wei , Parikh, Sameer A , Shanafelt, Tait D , Kenderian, Saad S. , Dyke, Daniel L. Van , Slager, Susan L.

Mayo Clinic

Blood | April 20, 2021 | Volume: 138 | Issue: 2 | Pages: 149-159

10.1182/blood.2020009813 | PMID 33876228 Get It

Abstract The utility of the chronic lymphocytic leukemia-international prognostic index (CLL-IPI) in predicting outcomes of individuals with Rai 0 stage CLL and monoclonal B-cell lymphocytosis (MBL) is unclear. We identified 969 individuals (415 MBL and 554 Rai 0 CLL; median age, 64 years; 65% men) seen at Mayo Clinic between 1 January 2001 and 1 October 2018, and ascertained time to first therapy (TTFT) and overall survival (OS). After a median follow up of 7 years, the risk of disease progression needing therapy was 2.9%/y for MBL (median, not reached) and 5%/y for Rai 0 CLL (median, 10.4 years). Among patients with low, intermediate, and high/very high-risk CLL-IPI risk groups, the estimated 5-year risk of TTFT was 13.5%, 30%, and 58%, respectively, P< .0001 (c-statistic = 0.69); and the estimated 5-year OS was 96.3%, 91.5%, and 76%, respectively, P< .0001 (c-statistic = 0.65). In a multivariable analysis of absolute B-cell count with individual factors of the CLL-IPI, the absolute B-cell count was associated with shorter TTFT (hazard ratio [HR] for each 10 × 109/L increase: 1.31; P< .0001) and shorter OS (HR: 1.1; P = .02). The OS of the entire cohort was similar to that of the age- and sex-matched general population of Minnesota (P = .17), although Rai 0 CLL patients with high and very high-risk CLL-IPI score had significantly shorter OS (P= .01 and P= .0001, respectively). The results of this study demonstrate the ability of CLL-IPI to predict time from diagnosis to first treatment (an end point not affected by therapy) in a large cohort of patients whose only manifestation of disease is a circulating clonal lymphocyte population.
Author response: Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, Lili, Langbein, Lauren , Cho, Eun-Ah , Niu, Xiaohua , Jiang, Wei , Zhong, Zhijiu , Jagannathan, Geetha , Dulaimi, Essel, Testa, Joseph R. , Wang, Yuxin , Stark, George R. , Peiper, Stephen, Yang, Haifeng , Liu, Zongzhi Z. , Cai, Weijia , Na, Jie, Cai, Wesley L. , Uzzo, Robert G. , Sun, Jianxin , Xu, Yaomin , Yan, Qin

Mayo Clinic

No container title available | April 19, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.37925.sa2 Get It

Incidence, risk factors, treatment, and consequences of antibody‐mediated kidney transplant rejection: A systematic review
Hart, Allyson , Singh, Devender , Brown, Sarah , Wang, Jeffrey , Kasiske, Bertram L. , Singh, Devender

Mayo Clinic

Clinical Transplantation | April 17, 2021 | Volume: 35 | Issue: 7 | Pages: No page available

10.1111/ctr.14320 | PMID 33864724 Get It

Abstract Background Antibody‐mediated rejection (AMR) is a leading cause of kidney allograft failure, but its incidence, risk factors, and outcomes are not well understood. Methods We searched Ovid MEDLINE, Cochrane, EMBASE, and Scopus from January 2000 to January 2020 to identify published cohorts of ≥500 incident adult or 75 pediatric kidney transplant recipients followed for ≥1 year post‐transplant. Results At least two reviewers screened 5061 articles and abstracts; 28 met inclusion criteria. Incidence of acute AMR was 1.1%‐21.5%; most studies reported 3%‐12% incidence, usually within the first year post‐transplant. Few studies reported chronic AMR incidence, from 7.5%‐20.1% up to 10 years. Almost all patients with acute or chronic AMR received corticosteroids and intravenous immunoglobulin; most received plasmapheresis, and approximately half with rituximab. Most studies examining death‐censored graft failure identified AMR as an independent risk factor. Few reported refractory AMR rates or outcomes, and none examined costs. Most studies were single‐center and varied greatly in design. Conclusions Cohort studies of kidney transplant recipients demonstrate that AMR is common and associated with increased risk of death‐censored graft failure, but studies vary widely regarding populations, definitions, and reported incidence. Gaps remain in our understanding of refractory AMR, its costs, and resulting quality of life.
Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294
McGee, Kiaran P. , Hwang, Ken‐Pin, Sullivan, Daniel C. , Hu, Yanle , Debbins, Josef P., Paulson, E.S. , Olsen, Jeffrey R., Hua, Chia‐Ho , Warner, Lizette, Tyagi, Neelam , Chung, Caroline , Kurhanewicz, John V. , Wang, Jihong , Li, Wen , Daniel, J. , Moros, Eduardo G.

Mayo Clinic

Medical Physics | April 17, 2021 | Volume: 48 | Issue: 7 | Pages: No page available

10.1002/mp.14884 | PMID 33864283 Get It

PurposeA magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
Patient-reported outcome improvements at 24-month follow-up after fusion added to decompression for grade I degenerative lumbar spondylolisthesis: a multicenter study using the Quality Outcomes Database
Bisson, Erica F. , Bydon, Mohamad , Alvi, Mohammed Ali , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Yew, Andrew, Haid, Regis W., Chan, Andrew K. , Mummaneni, Praveen V. , Alvi, Mohammed A, Alvi, Mohammed Ali , Guan, Jian , Goyal, Anshit

Mayo Clinic

Journal of Neurosurgery: Spine | April 16, 2021 | Volume: 35 | Issue: 1 | Pages: 42-51

10.3171/2020.9.spine201082 | PMID 33862593 Get It

OBJECTIVE The ideal surgical management of grade I lumbar spondylolisthesis has not been determined despite extensive prior investigations. In this cohort study, the authors used data from the large, multicenter, prospectively collected Quality Outcomes Database to bridge the gap between the findings in previous randomized trials and those in a more heterogeneous population treated in a typical practice. The objective was to assess the difference in patient-reported outcomes among patients undergoing decompression alone or decompression plus fusion. METHODS The primary outcome measure was change in 24-month Oswestry Disability Index (ODI) scores. The minimal clinically important difference (MCID) in ODI score change and 30% change in ODI score at 24 months were also evaluated. After adjusting for patient-specific and clinical factors, multivariable linear and logistic regressions were employed to evaluate the impact of fusion on outcomes. To account for differences in age, sex, body mass index, and baseline listhesis, a sensitivity analysis was performed using propensity score analysis to match patients undergoing decompression only with those undergoing decompression and fusion. RESULTS In total, 608 patients who had grade I lumbar spondylolisthesis were identified (85.5% with at least 24 months of follow-up); 140 (23.0%) underwent decompression alone and 468 (77.0%) underwent decompression and fusion. The 24-month change in ODI score was significantly greater in the fusion plus decompression group than in the decompression-only group (−25.8 ± 20.0 vs −15.2 ± 19.8, p < 0.001). Fusion remained independently associated with 24-month ODI score change (B = −7.05, 95% CI −10.70 to −3.39, p ≤ 0.001) in multivariable regression analysis, as well as with achieving the MCID for the ODI score (OR 1.767, 95% CI 1.058–2.944, p = 0.029) and 30% change in ODI score (OR 2.371, 95% CI 1.286–4.371, p = 0.005). Propensity score analysis resulted in 94 patients in the decompression-only group matched 1 to 1 with 94 patients in the fusion group. The addition of fusion to decompression remained a significant predictor of 24-month change in the ODI score (B = 2.796, 95% CI 2.228–13.275, p = 0.006) and of achieving the 24-month MCID ODI score (OR 2.898, 95% CI 1.214–6.914, p = 0.016) and 24-month 30% change in ODI score (OR 2.300, 95% CI 1.014–5.216, p = 0.046). CONCLUSIONS These results suggest that decompression plus fusion in patients with grade I lumbar spondylolisthesis may be associated with superior outcomes at 24 months compared with decompression alone, both in reduction of disability and in achieving clinically meaningful improvement. Longer-term follow-up is warranted to assess whether this effect is sustained.
The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial
Wood, Marie , Liu, Heshan , Storrick, Elizabeth, Zahrieh, David , Le-Petross, H. Carisa , Zekan, Patricia J., Kemeny, Margaret, Charlamb, Jayne R. , Wang, Lili X, Unzeitig, Gary, Johnson, Candace S. , Marshall, James R. , Charlamb, Jayne R , Johnson, Candace S , Garber, J. E. , Le‐Petross, Huong T. , Jung, Sin‐Ho , Garber, Judy E. , Bedrosian, Isabelle

Mayo Clinic

Cancer Prevention Research | April 13, 2021 | Volume: 14 | Issue: 7 | Pages: 753-762

10.1158/1940-6207.capr-20-0581 | PMID 33849913 Get It

Abstract Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and toxicity limits use of these agents. Vitamin D is a potential prevention therapy for both ER+ and ER− disease and is safe with few side effects. This study evaluates the effect of 1-year of vitamin D supplementation on mammographic density (MD), a biomarker of breast cancer risk in a multicenter randomized controlled trial. Premenopausal women with ≥25% MD and no history of cancer were randomly assigned to 2,000 international units (IU) of vitamin D or placebo orally daily for 1 year. Change in percent MD was evaluated using Cumulus software after all participants completed treatment. Three hundred women enrolled between January 2011 and December 2013 with a mean age of 43 and diverse ethnicity [14% Hispanic, 12% African American (AA)]. Supplementation significantly increased vitamin D levels compared with placebo (14.5 ng/mL vs. −1.6 ng/mL; P &lt; 0.0001) with all participants on the vitamin D arm achieving vitamin D sufficiency at 12 months. Vitamin D was safe and well tolerated. After adjustment for baseline MD, the mean between-arm difference (vitamin D vs. placebo) at 1 year was −0.75 (−0.26, 1.76; P = 0.56). A greater effect was seen for women with ≥50% MD and AA women, although neither reached significance. This randomized controlled trial demonstrated significant improvement in vitamin D levels with 2,000 IU for 1 year, with 100% of supplemented women achieving sufficiency. However, a null effect was seen regarding change in MD for premenopausal women (the primary outcome of the study). Prevention Relevance: Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and are underutilized due to toxicity and side effects. Vitamin D is a potential prevention therapy for both ER+ and ER− disease and is safe with few side effects.
Differential mRNA Expression in Ileal Mucosal Biopsies of Patients With Diarrhea- or Constipation-Predominant Irritable Bowel Syndrome
Carlson, Paula, Chedid, Victor , Maselli, Daniel B. , Taylor, Ann, McKinzie, Sanna, Camilleri, Michael , Chedid, Victor G , Wang, Xiao‐Jing

Mayo Clinic

Clinical and Translational Gastroenterology | April 12, 2021 | Volume: 12 | Issue: 4 | Pages: e00329

10.14309/ctg.0000000000000329 | PMID 33843785 Get It

INTRODUCTION: Previous studies in patients with irritable bowel syndrome (IBS) showed immune activation, secretion, and barrier dysfunction in duodenal, jejunal, or colorectal mucosa. This study aimed to measure ileal mucosal expression of genes and proteins associated with mucosal functions. METHODS: We measured by reverse transcription polymerase chain reaction messenger RNA (mRNA) expression of 78 genes (reflecting tight junction proteins, chemokines, innate immunity, ion channels, and transmitters) and 5 proteins (barrier, bile acid receptor, and ion exchanger) in terminal ileal mucosa from 11 patients with IBS-diarrhea (IBS-D), 17 patients with IBS-constipation (IBS-C), and 14 healthy controls. Fold changes in mRNA were calculated using 2 (−Δ, ΔCT) formula. Group differences were measured using analysis of variance. Protein ratios relative to healthy controls were based on Western blot analysis. Nominal P values ( P < 0.05) are reported. RESULTS: In ileal mucosal biopsies, significant differences of mRNA expression in IBS-D relative to IBS-C were upregulation of barrier proteins (TJP1, FN1, CLDN1, and CLDN12), repair function (TFF1), and cellular functions. In ileal mucosal biopsies, mRNA expression in IBS-C relative to healthy controls was reduced GPBAR1 receptor, myosin light chain kinase (MYLK in barrier function), and innate immunity (TLR3), but increased mRNA expression of cadherin cell adhesion mechanisms (CTNNB1) and transport genes SLC9A1 (Na-H exchanger [NHE1]) and INADL (indirect effect on ion transport). DISCUSSION: These data support a role of ileal mucosal dysfunction in IBS, including barrier dysfunction in IBS-D and alterations in absorption/secretion mechanisms in IBS-C.